NORADRENALINE IN PRETERM INFANTS WITH CARDIOVASCULAR COMPROMISE
John Hunter Childrens Hospital Noradrenaline (NA) is beneficial in the treatment of term newborns with cardiovascular compromise due to sepsis or pulmonary hypertension, but experiences with NA in preterm infants are limited. The aim of this study is to describe the efficacy and safety of NA in preterm infants. Patient records of preterm infants < =32 weeks' gestation admitted to two hospitals between 2004 and 2015 and who received NA were reviewed for perinatal morbidities and mortality. Clinical details were collected at the time of NA use, and response on blood pressure, perfusion and oxygenation was documented as well as possible side effects. Forty-eight infants with primary diagnoses of sepsis (63 %) and pulmonary hypertension (23 %) received NA. Normotension was achieved at a median of 1 h in all but one infant at a median dose of 0.5 mcg/kg/min. Infants who died (46 %) were of younger gestational age and had worse cardiovascular function at start of NA compared to infants who survived. Tachycardia was common (31 %), but no additional effects were found on kidney or liver function.
Conclusion: NA appears to be tolerated safely by preterm infants with no major side effects. However, effectiveness needs to be studies further in structured trials. Background: Both pain and common pharmacological analgesics may adversely affect newborn neurodevelopmental outcomes. We investigated the feasibility and safety of magnetic acupuncture (MA) as an adjunctive analgesic for heel pricks in newborn infants.
MAGNETIC NON-INVASIVE ACUPUNCTURE FOR INFANT COMFORT (MAGNIFIC) IN HEEL PRICKS-
Method: After parental consent, infants requiring heel pricks for blood collection were randomised to either MA (n = 21) or placebo (P) (n = 19) between 15th Aug -10th Nov 2016. Five MA or placebo stickers were placed on auricular acupuncture sites on each ear for 3 days by an unblinded investigator. Pain responses were assessed with the Premature Infant Pain Profile (PIPP) by blinded clinicians 15 minutes before and after and during each heel prick. The study was registered in the Australian and New Zealand Clinical Trial Registry (ACTRN1261 6001229460).
Results: Infants were similar in birth weight (MA:2303 g, P:2104 g) and age at heel prick (MA:5.3, P:4.5 days). Mean (SD) PIPP scores were similar before (MA:1.7(1.4), P:2.1(1.9)) and after (MA:1.6(1.4), P: 2.1(1.7)) heel pricks but were lower in MA infants during heel pricks (MA:5.9(3.7) v P: 8.3(4.7), p = 0.04). One-way ANCOVA modelling demonstrated a significant effect of MA on heel prick PIPP scores even after controlling for analgesia (p = 0.043, eta 2 = 0.07). No differences were noted in heart rate, SpO 2 or incidence of adverse effects (e.g. local skin reactions, sticker displacement). Conclusions: Auricular MA is feasible in neonates and may reduce PIPP scores during common procedures like heel pricks. Further studies are required to determine the impact of MA on other painful procedures and on neurodevelopmental outcomes. Background: Even though hypoglycaemia is the most common metabolic abnormality in neonates, its definition remains controversial. Our new hypoglycaemia screening pathway defined hypoglycaemia as a plasma glucose concentration of less than 2.9 mmol/L in the first 48 hours of life (J Ped 2015; 167:238-245) .
AUDIT OF THE BLOOD SUGAR PROFILES OF AT-RISK
Method: Blood glucose profiles of infants at-risk of hypoglycaemia born during August to November 2016 were analysed.
